New Delhi, April 4 (IANS) India’s drug regulators are stepping up oversight of fast-growing weight-loss and diabetes therapies, particularly GLP-1 receptor agonists, amid rising demand and the anticipated entry of cheaper generic versions into the domestic market.The move comes as the Indian Pharmacopoeia Commission (IPC), which functions under the Ministry of Health, has been tasked with systematically collecting and analysing adverse event reports linked to these drugs.The initiative aims to…
Trending
- The Last Salute Movie Review 2026: An Unmissable Tribute That Soars With Raw MiG-21 Stories
- Hi Movie Review 2026: Kavin-Nayanthara’s Delightful Rom-Com Is a Refreshing Watch
- Once More (2026) Movie Review: Arjun Das and Aditi Shankar’s Heartfelt Tamil Romance Is A Beautiful Second-Chance Love Story
- Babita Singh Reporting Review 2026: A Powerful, Unforgettable Journey Into Courage and Truth
- Toxic: A Fairy Tale For Grown-Ups 2026 Movie Review— Yash Delivers A Stunning Gangster Spectacle
- Bindi, Tilak, or Sindoor: Here’s What That Dot on the Forehead Actually Means
- Bethlehem Kudumba Unit Movie Review 2026: A Heartwarming Onam Blockbuster That Wins Hearts
- Irumudi Movie Review 2026: Ravi Teja Delivers a Powerful Comeback Performance in Shiva Nirvana’s Emotional Thriller